Physician profile
David R Sheff
NPI 1508111402
$4,679.95
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $910 · 2021: $1,163 · 2022: $805 · 2023: $1,027 · 2024: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,144.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $543.59 | 2019-2023 | Prolia, Evenity, Repatha |
| Novo Nordisk INC | $486.07 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $443.45 | 2021-2024 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $430.35 | 2019-2024 | Farxiga, Breztri |
| Pfizer INC. | $425.17 | 2019-2024 | |
| Glaxosmithkline, LLC. | $268.33 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.30 | 2019-2023 | Tradjenta, Trijardy Xr, Glyxambi |
| Astellas Pharma US INC | $224.17 | 2020-2023 | Myrbetriq, Veozah |
| Merck Sharp & Dohme LLC | $197.15 | 2019-2022 | |
| Allergan, INC. | $164.77 | 2019-2020 | |
| Lilly USA, LLC | $160.15 | 2021-2023 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $136.77 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.24 | 2021-2023 | Trulance, Xifaxan |
| Mylan Specialty L.P. | $96.02 | 2021-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $93.58 | 2019-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $82.28 | 2022 | |
| Abbott Laboratories | $69.07 | 2021-2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $68.85 | 2023-2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $68.42 | 2020-2021 | |
| Amarin Pharma, INC. | $54.04 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $51.15 | 2020-2022 | |
| Esperion Therapeutics, INC. | $49.90 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.36 | 2021-2022 | |
| Genentech USA, INC. | $38.31 | 2019-2021 | |
| Coopersurgical, INC. | $25.53 | 2023 | Paragard T 380a |
| Idorsia Pharmaceuticals US INC | $19.21 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $18.24 | 2022 | |
| Azurity Pharmaceuticals, INC. | $15.60 | 2023 | Edarbi |
| Otsuka America Pharmaceutical, INC. | $14.61 | 2023 | Rexulti |
| Sanofi Pasteur INC. | $13.73 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sheff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.